AVLN — Avalyn Pharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1540171 ·
Last close
$27.92
Market Cap
$1.24B
52W High
$40.17
52W Low
$22.24
ADV30
443,247
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -33,094,000 | -29,655,000 | 399,296,000 | 145,424,000 | 29,046,000 |
| Jun 2026 | 0 | — | -31,290,000 | -28,935,000 | 425,448,000 | 264,197,000 | 27,102,000 |
| Mar 2026 | 0 | — | -27,909,000 | -26,869,000 | 135,663,000 | 92,310,000 | 399,908,000 |
| Dec 2025 | 0 | — | -25,476,000 | -23,926,000 | 148,881,000 | 52,315,000 | 387,537,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-95,939,000
Investing CF
$-76,252,000
Financing CF
$421,419,000
CapEx
$-595,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.20
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-321,167,000
Inventory
—
Receivables
$1,674,000
ST Investments
$88,228,000
EBIT TTM
$-93,128,000
Pretax Income TTM
$-93,498,000
Interest Exp TTM
$370,000
Analysts
5
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -91,292,000 | -85,204,000 | 148,881,000 | 387,537,000 | -238,656,000 | -81,484,000 |
| Dec 2024 | 0 | -57,121,000 | -49,744,000 | 124,519,000 | 299,041,000 | -174,522,000 | -48,368,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$425,448,000
Forward EPS
$-2.58
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $40.00 · spot: $27.69 · call volume: 0 · put volume: 26Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.24B | $29.10 | — |
| KARD | Kardigan, Inc. | $1.23B | $13.19 | — |
| GHRS | GH Research PLC | $1.25B | $18.27 | — |
| SLN | Silence Therapeutics plc | $1.23B | $19.80 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.23B | $13.14 | — |
News headlines (Yahoo Finance, 1h cache)
Avalyn: Q3 Earnings Snapshot
2026-11-12 13:26 · Yahoo
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 13:00 · Yahoo
Avalyn to Present at Upcoming Investor Conferences
2026-11-03 13:00 · Yahoo
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
2026-09-16 20:01 · Yahoo
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
2026-09-08 12:00 · Yahoo
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
2026-08-24 20:01 · Yahoo
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-12 12:00 · Yahoo
Avalyn to Participate in the Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-06-03 11:00 · Yahoo
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
2026-06-06 02:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.